Log in

ASX:ANR - Anatara Lifesciences Stock Price, Forecast & News

0.00 (0.00 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
Now: A$0.20
50-Day Range
MA: A$0.21
52-Week Range
Now: A$0.20
Volume12,500 shs
Average VolumeN/A
Market Capitalization$9.91 million
P/E RatioN/A
Dividend YieldN/A
Anatara Lifesciences Limited engages in the development of non-antibiotic oral solutions for gastro intestinal diseases in animals and humans in Australia. Its lead product includes Detach, a non-antibiotic treatment to aid in the control of diarrhoeal diseas. The company is also developing bromelain formulations for gastrointestinal health. Anatara Lifesciences Limited is based in Brisbane, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 7 3394 8202



Sales & Book Value

Annual Sales$663,405.00
Cash FlowA$0.10 per share
Book ValueA$0.12 per share



Market Cap$9.91 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ANR News and Ratings via Email

Sign-up to receive the latest news and ratings for ANR and its competitors with MarketBeat's FREE daily newsletter.

Anatara Lifesciences (ASX:ANR) Frequently Asked Questions

What is Anatara Lifesciences' stock symbol?

Anatara Lifesciences trades on the ASX under the ticker symbol "ANR."

Has Anatara Lifesciences been receiving favorable news coverage?

News stories about ANR stock have been trending somewhat negative on Saturday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anatara Lifesciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Anatara Lifesciences.

Who are some of Anatara Lifesciences' key competitors?

What other stocks do shareholders of Anatara Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anatara Lifesciences investors own include Brompton Oil Split Cl A (OSP), Eagle Materials (EXP), BHP Group (BHP), Ameriprise Financial (AMP) and Woodside Petroleum (WPL).

Who are Anatara Lifesciences' key executives?

Anatara Lifesciences' management team includes the folowing people:
  • Dr. Tracie Elizabeth Ramsdale, Interim CEO & Exec. Director (Age 56)
  • Dr. Tracey Mynott, Co-Founder, Chief Scientific Officer and R&D Director
  • Dr. Michael L. West Ph.D., Chief Operating Officer (Age 55)
  • Dr. Terence Jean Brown, Chief Devel. Officer (Age 56)
  • Mr. Alan Dowling, Group Accountant

What is Anatara Lifesciences' stock price today?

One share of ANR stock can currently be purchased for approximately A$0.20.

How big of a company is Anatara Lifesciences?

Anatara Lifesciences has a market capitalization of $9.91 million and generates $663,405.00 in revenue each year. View Additional Information About Anatara Lifesciences.

What is Anatara Lifesciences' official website?

The official website for Anatara Lifesciences is http://www.anataralifesciences.com/.

How can I contact Anatara Lifesciences?

The company can be reached via phone at 61 7 3394 8202.

MarketBeat Community Rating for Anatara Lifesciences (ASX ANR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  8 (Vote Outperform)
Underperform Votes:  9 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Anatara Lifesciences and other stocks. Vote "Outperform" if you believe ANR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel